Sergei M Gryaznov

USPTO Granted Patents = 83 (Patent Applications = 23)

CIPO Patents = 8 (Patent Applications = 10)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 2.7

ph-index = 26

Forward Citations = 2,987(Granted Patents)

Forward Citations (Not Self Cited) = 2,586(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Mateo, CA (US) (1995 - 2024)
Chicago, IL (US) (2024)

Company Filing History:

Lynx Therapeutics, Inc.

patents

8 out of 2,123

Northwestern University

Janssen Biopharma, Inc.

patents

6. 4 out of 5,469

The University of Texas System

patents

7. 2 out of 4

Exicure Operating Company

patents

8. 2 out of 2,078

Janssen Pharmaceutica Nv

patents

9. 1 out of 2

Perkin-elmer Corporation, Applied Biosystems, Inc.

patents

10. 1 out of 30

Healthpartners Research Foundation

patents

11. 1 out of 15,502

University of California

patents

12. 1 out of 975

University of Rochester

patents

13. 3 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

Modified Nucleoside Phosphoramidites

Guanine Analogs

Telomerase Substrates

Liposomal Particles

Oligonucleotide Constructs

Spherical Nucleic Acids

Anti-TNF Compounds

RNA Amidates

Thioamidates

C-myc Antisense Oligonucleotides

Telomere Length Effectors

Multivalent Delivery

83 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428441 - Modified nucleoside phosphoramidites (2025-09-30),

2. 12398162 - Guanine analogs as telomerase substrates and telomere length affectors (2025-08-26),

3. 12077757 - Modified oligonucleotides and methods of use (2024-09-03),

4. 12070472 - Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds (2024-08-27),

5. 12030907 - Modified nucleoside phosphoramidites (2024-07-09),

6. 11957788 - Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications (2024-04-16),

7. 11883535 - Liposomal particles, methods of making same and uses thereof (2024-01-30),

8. 11453881 - Modified oligonucleotides for use in treatment of tauopathies (2022-09-27),

9. 11279720 - Guanine analogs as telomerase substrates and telomere length affectors (2022-03-22),

10. 11180524 - Modified nucleoside phosphoramidites (2021-11-23),

11. 11123294 - Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications (2021-09-21),

12. 10905767 - Oligonucleotide constructs and uses thereof (2021-02-02),

13. 10894963 - Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use (2021-01-19),

14. 10837018 - Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use (2020-11-17),

15. 10793859 - Modified oligonucleotides and methods of use (2020-10-06),

Title: The Innovations of Sergei M Gryaznov: A Pioneer in Oligonucleotide Research

Introduction

Sergei M Gryaznov, based in San Mateo, California, is a prominent inventor with an impressive portfolio of 81 patents. His work primarily focuses on the development of modified oligonucleotides and their applications in combating various diseases, showcasing his contributions to the field of pharmaceuticals and biotechnology.

Latest Patents

Among his latest patents is a significant innovation involving modified oligonucleotides. This invention encompasses modifications at the 2' and/or 3' position(s), providing methods for making and using these oligonucleotides, particularly in the fight against Hepatitis B virus (HBV). Another critical patent addresses the treatment of drug-resistant proliferative diseases using telomerase-mediated compounds. This invention details pharmaceutical compositions involving 6-mercaptopurine ribosides and analogues for treating cancer and other hyperproliferative diseases, leading to the induction of cell death in telomerase-active cells.

Career Highlights

Throughout his career, Gryaznov has made substantial contributions while working with notable companies such as Geron Corporation and Lynx Therapeutics, Inc. His experiences at these organizations have allowed him to refine his innovations and collaborate on cutting-edge research.

Collaborations

In addition to his own work, Gryaznov has collaborated with esteemed colleagues, including Krisztina Pongracz and Ronald G Schultz. These collaborations have furthered advancements in the understanding and application of his patented technologies.

Conclusion

Sergei M Gryaznov's extensive portfolio of patents and his commitment to innovation reflect his vital role in advancing the field of biotechnology. His groundbreaking work on modified oligonucleotides and telomerase-related compounds has the potential to significantly impact the treatment of various diseases, marking him as a key figure in contemporary pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.